- Home
- Results news
- Kronox Lab Sciences
- Q2 FY27 results
Kronox Lab Sciences Q2 FY27 results: net profit up 105.7% to ₹13.74 crore, revenue up 116.3%
Kronox Lab Sciences Limited reported standalone Q2 FY27 revenue of ₹55.22 crore, up 116.3% from Q2 FY26 and 94.5% from Q1 FY27. Net profit rose to ₹13.74 crore from ₹6.68 crore a year earlier, while EBITDA margin was 31.6%.
Key points
- Revenue was ₹55.22 crore in Q2 FY27, up ₹29.69 crore or 116.3% from Q2 FY26.
- Net profit was ₹13.74 crore, up ₹7.06 crore or 105.7% from the year-ago quarter.
- EBITDA was ₹17.44 crore with a 31.6% margin, compared with 33.9% in Q2 FY26.
- Basic EPS was ₹3.70, compared with ₹1.82 in Q2 FY26 and ₹2.00 in Q1 FY27.
- Total assets rose to ₹138.1 crore and total equity to ₹127.99 crore as of 30 September 2026.
How did Kronox Lab Sciences perform in Q2 FY27?
Kronox Lab Sciences reported standalone revenue of ₹55.22 crore in Q2 FY27, up 116.3% from ₹25.53 crore in Q2 FY26 and 94.5% from ₹28.39 crore in Q1 FY27. Total income was ₹57.39 crore. The quarter ended on 30 September 2026, and the figures were unaudited; the filing presents standalone results rather than consolidated results.
EBITDA was ₹17.44 crore, up 101.6% from ₹8.65 crore in Q2 FY26 and 93.8% from ₹9 crore in Q1 FY27. The EBITDA margin was 31.6%, compared with 33.9% a year earlier and 31.7% in the previous quarter. Profit before tax was ₹18.54 crore, while net profit was ₹13.74 crore, up 105.7% year on year and 88.2% sequentially. Basic EPS was ₹3.70.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 55.22 | 28.39 | 25.53 | +116.3% | +94.5% |
| Other income | 2.17 | 1.30 | 1.04 | +108.7% | +66.9% |
| Total expenses | 38.84 | 19.87 | 17.40 | +123.2% | +95.5% |
| EBITDA | 17.44 | 9 | 8.65 | +101.6% | +93.8% |
| EBITDA margin | 31.6% | 31.7% | 33.9% | −2.3 pp | −0.1 pp |
| Profit before tax | 18.54 | 9.81 | 9.18 | +102.0% | +89.0% |
| Tax | 4.80 | 2.51 | 2.50 | +92.0% | +91.2% |
| Net profit | 13.74 | 7.30 | 6.68 | +105.7% | +88.2% |
| EPS (₹) | 3.70 | 2.00 | 1.82 | +103.3% | +85.0% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Kronox Lab Sciences' costs and profit?
Total expenses increased to ₹38.84 crore in Q2 FY27 from ₹17.40 crore in Q2 FY26. Cost of materials consumed rose by ₹15.97 crore to ₹26.18 crore, employee benefit expenses increased by ₹2 crore to ₹3.84 crore, and other expenses were ₹4.08 crore higher at ₹7.76 crore. Finance costs increased by ₹0.07 crore to ₹0.11 crore, while depreciation rose by ₹0.48 crore to ₹0.95 crore. The filing does not state why these costs changed.
Other income was ₹2.17 crore, up ₹1.13 crore from ₹1.04 crore in the year-ago quarter. There was no exceptional item in either quarter. Profit before tax increased by ₹9.36 crore to ₹18.54 crore, while tax expense rose by ₹2.30 crore to ₹4.80 crore. The PAT margin was 24.9%, compared with 26.1% in Q2 FY26.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 26.18 | 10.21 | +15.97 | +156.4% |
| Employee cost | 3.84 | 1.84 | +2 | +108.7% |
| Finance costs | 0.11 | 0.04 | +0.07 | +175.0% |
| Depreciation | 0.95 | 0.47 | +0.48 | +102.1% |
| Other expenses | 7.76 | 3.68 | +4.08 | +110.9% |
| Total expenses | 38.84 | 17.40 | +21.44 | +123.2% |
| Other income | 2.17 | 1.04 | +1.13 | +108.7% |
| Tax | 4.80 | 2.50 | +2.30 | +92.0% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
As of 30 September 2026, total assets were ₹138.1 crore, compared with ₹127.52 crore at 31 March 2026. Total equity rose to ₹127.99 crore from ₹116.13 crore, while borrowings fell from ₹1.61 crore to nil. Cash and cash equivalents increased to ₹9.44 crore from ₹2.75 crore. Inventories were ₹7.4 crore, trade receivables were ₹18.82 crore and trade payables were ₹8.33 crore.
For H1 FY27, net cash from operating activities was ₹16.04 crore, compared with ₹10.5 crore in H1 FY26. Investing cash flow was negative ₹5.77 crore, compared with negative ₹11.64 crore, and financing cash flow was negative ₹3.58 crore, compared with ₹0.76 crore. Capital expenditure was ₹1.83 crore, compared with ₹3.03 crore a year earlier.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 138.10 | 127.52 |
| Total equity | 127.99 | 116.13 |
| Borrowings | 0 | 1.61 |
| Cash and equivalents | 9.44 | 2.75 |
| Inventories | 7.40 | 8.37 |
| Trade receivables | 18.82 | 21.18 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 16.04 | 10.50 |
| Cash from investing | −5.77 | −11.64 |
| Cash from financing | −3.58 | 0.76 |
| Capital expenditure | 1.83 | 3.03 |
Source: Company's results filing (XBRL).
How has Kronox Lab Sciences done over the last 8 quarters?
Revenue reached its highest level in the reported series at ₹55.22 crore in Q2 FY27, after ₹28.39 crore in Q1 FY27. Net profit also peaked at ₹13.74 crore, following ₹7.30 crore in the previous quarter. The pattern shows a sharp sequential rise in both measures in the latest quarter.
EBITDA margin reached its highest level at 36.4% in Q4 FY26 and its lowest at 29.7% in Q4 FY25. It was 31.6% in Q2 FY27, below 33.9% in Q2 FY26 and 31.7% in Q1 FY27. Revenue rose year on year in each of the last 2 quarters, while profit rose year on year in each of the last 7 quarters.
What did the auditors point out?
The statutory auditors carried out a limited review of the unaudited financial results and expressed an unmodified review report. They included an Emphasis of Matter paragraph noting the transfer of equity shares representing 64.26% of the paid-up equity share capital to Indo Borax & Chemicals Limited on 29 September 2026. Indo Borax Chemicals Limited consequently became the holding company, and the board and key managerial personnel changed with effect from that date. The auditors stated that their conclusion was not modified in this respect.
How did Kronox Lab Sciences shares react?
The filing was announced during market hours on 5 November 2026. The stock was unchanged after 5 minutes, fell 2.6% after 15 minutes and was down 1.6% after 30 minutes from the price when the filing appeared. No reaction-day, next-day or five-day close was available, so a comparison with the industry median could not be made.
Earlier results-day reactions were mixed but mostly negative: the stock fell 10.7% on 12 August 2026, rose 1.1% on 21 May 2026 and fell 1.6% on 14 February 2026. The remaining listed reactions included declines on 11 November 2025, 11 August 2025, 22 May 2025, 31 January 2025 and 12 November 2024.
| After the filing | Stock |
|---|---|
| 5 minutes | +0.0% |
| 15 minutes | −2.6% |
| 30 minutes | −1.6% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 12 August 2026 | −10.7% |
| 21 May 2026 | +1.1% |
| 14 February 2026 | −1.6% |
| 11 November 2025 | −1.9% |
| 11 August 2025 | −5.5% |
| 22 May 2025 | −2.5% |
| 31 January 2025 | −3.3% |
| 12 November 2024 | −2.0% |
Source: MarketPing price-reaction measurement.
How did other Specialty Chemicals companies do?
Among 58 other Specialty Chemicals companies compared for the quarter, the median revenue growth was 28.3%. Of the peers for which profit was compared, 47 reported higher profit. Revenue grew more slowly than Kronox Lab Sciences at 51 peers and faster at 7 peers. The peer comparison was available as of 5 November 2026.
| Kronox Lab Sciences revenue growth (YoY) | +116.3% |
|---|---|
| Median of 58 other Specialty Chemicals companies | +28.3% |
| Companies with slower revenue growth than Kronox Lab Sciences | 51 of 58 |
| Companies with faster revenue growth than Kronox Lab Sciences | 7 of 58 |
| Companies whose net profit rose | 47 of 54 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Kronox Lab Sciences' revenue in Q2 FY27?
Revenue from operations was ₹55.22 crore, up 116.3% from ₹25.53 crore in Q2 FY26 (standalone).
Did Kronox Lab Sciences make a profit in Q2 FY27?
Yes. Net profit was ₹13.74 crore, against a net profit of ₹6.68 crore in Q2 FY26.
What was Kronox Lab Sciences' EPS in Q2 FY27?
Basic earnings per share were ₹3.70, against ₹1.82 in Q2 FY26.
When did Kronox Lab Sciences announce its Q2 FY27 results?
On 5 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Consider And Approve Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30, 2026 (BSE, 30 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting (BSE, 5 November 2026) · PDF
- Results - Financial Results For The Quarter And Half Year Ended September 30, 2026 (BSE, 5 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.